Skip to main content

NASDAQ:KOOL - Cesca Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.15
▼ -0.24 (-10.04%)
Get New Cesca Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KOOL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KOOL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cesca Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.15.

N/A

The current consensus among 0 investment analysts is to n/a stock in Cesca Therapeutics. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/3/2019HC WainwrightReiterated RatingBuy$6.50 ➝ $7.50Medium
i
8/14/2019HC WainwrightReiterated RatingBuy$1.00 ➝ $6.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/26/2019HC WainwrightSet Price TargetBuy$1.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/15/2018HC WainwrightSet Price TargetBuy$2.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/23/2018HC WainwrightInitiated CoverageBuy$0.54 ➝ $1.50High
i
Rating by S. Ramakanth at HC Wainwright
5/12/2017Maxim GroupReiterated RatingHoldLow
i
Rating by Jason Kolbert at Maxim Group
3/20/2017Maxim GroupReiterated RatingHoldLow
i
Rating by Jason Kolbert at Maxim Group
12/5/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason Kolbert at Maxim Group
8/1/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason Kolbert at Maxim Group
6/23/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason Kolbert at Maxim Group
6/7/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 5/16/2016 forward)
Cesca Therapeutics logo
Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.
Read More

Today's Range

Now: $2.15
$2.13
$2.39

50 Day Range

MA: $2.78
$2.11
$5.14

52 Week Range

Now: $2.15
$2.10
$7.00

Volume

463,579 shs

Average Volume

112,188 shs

Market Capitalization

$5.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Cesca Therapeutics?

The following Wall Street analysts have issued stock ratings on Cesca Therapeutics in the last twelve months:
View the latest analyst ratings for KOOL.

What is the current price target for Cesca Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cesca Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cesca Therapeutics in the next year.
View the latest price targets for KOOL.

What is the current consensus analyst rating for Cesca Therapeutics?

Cesca Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KOOL.

What other companies compete with Cesca Therapeutics?

How do I contact Cesca Therapeutics' investor relations team?

Cesca Therapeutics' physical mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company's listed phone number is 916-858-5100 and its investor relations email address is [email protected] The official website for Cesca Therapeutics is www.cescatherapeutics.com.